Role of Iron in Optimizing Responses of Anemic Cancer Patients to Erythropoietin

ONCOLOGY

Volumn 13, Issue 4, 1999, Pages 461-473

  Glaspy, John ^a   Cavill, Ivor ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FERRITIN; FERROUS SULFATE; FLUOROURACIL; IRON; IRON DEXTRAN; METHOTREXATE; NITROSOUREA DERIVATIVE; OXYGEN; RECOMBINANT ERYTHROPOIETIN; STEROID;

ANAPHYLAXIS; ANEMIA; BONE MARROW TOXICITY; CANCER; CHRONIC DISEASE; ERYTHROCYTE TRANSFUSION; FATIGUE; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON THERAPY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEALTH CARE COSTS; HEMATOCRIT; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; NEOPLASMS;

EID: 0032954894     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Silver RT: Introduction. Semin Oncol 21:1-2, 1994.
2. Reed WR, Hussey DH, DeGowin RL: Implications of the anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 308:9-15, 1994.
3. Fatigue may be most under-recognized, undertreated cancer-related symptom. Oncology News International 6(3):3, 1997.
4. Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12:2047-2050, 1986.
5. Overgaard J, Hansen HS, Jørgensen K, et al: Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 12:515-521, 1986.
6. Spivak JL: Cancer-related anemia: Its causes and characteristics. Semin Oncol 21(suppl 3):3-8, 1994.
7. Ludwig H, Fritz E, Leitgeb C, et al: Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4:161-167, 1993.
8. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21(suppl3):21-28, 1994.
9. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248-4267, 1997.
10. Macdougall IC: Poor response to erythropoietin should be fully investigated and treated. Br Med J 310:1424-1425, 1995.
11. Eschbach JW, Adamson JW: Recombinant human erythropoietin: Implications for nephrology. Am J Kidney Dis 11:203-209, 1988.
12. Sunder-Plassmann G, Hörl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995.
13. Cartwright GE. The anemia of chronic disorders. Semin Hematol 3:351-375, 1966.
14. Schooley JC, Kullgren B, Allison AC: Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 67:11-17, 1987.
15. Johnson RA, Waddelow TA, Caro J, et al: Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74:130-138, 1989.
16. Mamus SW, Beck-Schroeder S, Zanjani ED: Suppression of normal human erythropoiesis by gamma interferon in vitro: Role of monocytes and T lymphocytes. J Clin Invest 75:1496-1503, 1985.
17. Jelkmann W, Wolff M, Fandrey J: Modulation of the production of erythropoietin by cytokines: In vitro studies and their clinical implications. Contrib Nephrol 87:68-77, 1990.
18. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987-1994, 1992.
19. Moliterno AR, Spivak JL: Anemia of cancer. Hematol Oncol Clin North Am 10:345-363, 1996.
20. Wood PA, Hrushesky WJM: Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 95:1650-1659, 1995.
21. Schreml W, Lohrmann HP, Anger B: Stem cell defects after cytoreductive therapy in man. Exp Hematol 13(suppl 16):31-42, 1985.
22. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990.
23. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997.
24. Miller CB: The use of erythropoietin in cancer patients. Hematol/Oncol Ann 2:288-296, 1994.
25. Tsukuda M, Mochimatsu I, Nagahara T, et al: Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 36:52-56, 1993.
26. Vijayakumar S, Roach M, Wara W, et al: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys 26:721-729, 1993.
27. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 27:1147-1152, 1993.
28. Guest JF, Monro V, Cookson RF: The annual cost of blood transfusions in the United Kingdom. Clin Lab Haematol 20:111-118, 1998.
29. Wu H-S, Little AG: Perioperative blood transfusions and cancer recurrence. J Clin Oncol 6:1348-1354, 1988.
30. Robb N: Jehovah's Witnesses leading education drive as hospitals adjust to no blood requests. Can Med Assoc J 154:557-560, 1996.
31. Eschbach JW, Haley NR, Egrie JC, et al: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney lnt 42:407-416, 1992.
32. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987.
33. Nissenson AR: National cooperative rHu erythropoietin study in patients with chronic renal failure: A phase IV multicenter study. Am J Kidney Dis 18(suppl 1):24-33, 1991.
34. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990.
35. Cascinu S, Fedeli A, Del Ferro E, et al: Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062, 1994.
36. Wurnig C, Windhager R, Schwameis E, et al: Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 36:155-159, 1996.
37. Demetri G, Wade J, Cella D: Epoetin alfa improves quality of life (QOL) in cancer patients receiving cytotoxic treatment independent of disease response: Prospective clinical trial results (abstract). Blood 90(suppl 1):175a, 1997.
38. Beusterien KM, Nissenson AR, Port FK, et al: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7:763-773, 1996.
39. Ludwig H, Fritz E, Leitgeb C, et al: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063, 1994.
40. Abels R, Larholt K, Nelson R, et al: Prediction of response to recombinant human erythropoietin therapy in anemic cancer patients (abstract). Blood 82:92a, 1993.
41. Henry D, Abels R, Larholt K: Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-α) therapy in cancer patients (letter). Blood 85:1676-1678, 1995.
42. Cazzola M, Ponchio L, Pedrotti C, et al: Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434-441, 1996.
43. Eschbach JW, Abdulhadi MH, Browne JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989.
44. Macdougall IC, Hutton RD, Cavill I, et al: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299:157-158, 1989.
45. Eschbach JW, in Ersley AJ, Adamson JW, Eschbach JW, et al (eds): Erythropoietin: Molecular, Cellular and Clinical Biology, pp 211-226. Baltimore, Johns Hopkins University Press, 1991.
46. Van Wyck DB, Stivelman JC, Ruiz J, et al: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989.
47. Winearls CG, Oliver DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175-1178, 1986.
48. Cavill I: r-HuEPO: The iron dimension. Proceedings from a meeting held at The Royal Society of Medicine, London, November 29, 1995.
49. Cavill I, Macdougall I, Gokal R, et al: Iron management in patients on rHuEPO. Br J Renal Med 2:6-8, 1997.
50. Macdougall IC, Cavill I, Hulme B, et al: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 304:225-226, 1992.
51. Cazzola M, Ponchio L, Beguin Y, et al: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood 79:29-37, 1992.
52. Brugnara C, Chambers LA, Malynn E, et al: Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: Iron-deficient erythropoiesis in iron-replete subjects. Blood 81:956-964, 1993.
53. Biesma DH, van de Wiel A, Beguin Y, et al: Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 24:426-432, 1994.
54. Brugnara C, Colella GM, Cremins J, et al: Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 123:660-667, 1994.
55. Drücke TB, Bárány P, Cazzola M, et al: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 48:1-8, 1997.
56. National Kidney Foundation Dialysis Outcomes Quality Initiative: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(suppl 3):S192-S240, 1997.
57. Jacobs A, Path FRC, Worwood M: Ferritin in serum: Clinical and biochemical implications. N Engl J Med 292:951-956, 1975.
58. Bainton DF, Finch CA: The diagnosis of iron deficiency anemia. Am J Med 37:62-70, 1964.
59. Nissenson AR: Achieving target hematocrit in dialysis patients: New concepts in iron management. Am J Kidney Dis 30:907-911, 1997.
60. Dallman PR: Diagnosis of anemia and iron deficiency: Analytic and biologic variations of laboratory tests. Am J Clin Nutr 39:937-941, 1984.
61. Statland BE, Winkel P, Bokeland H: Variation of serum iron concentration in your g healthy men: Within-day and day-to-day changes. Clin Biochem 9:26-31, 1976.
62. Cavill I: Diagnostic methods. Clin Haematol 11:259-273, 1982.
63. Kalantar-Zadeh K, Kleiner M, Dunne E, et al: Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31:263-272, 1998.
64. Ali M, Rigolosi R, Fayemi AO, et al: Failure of serum ferritin levels to predict bonemarrow iron content after intravenous iron-dextran therapy. Lancet 1:652-655, 1982.
65. Konijin AM, Hershko C: Ferritin synthesis in inflammation: I. Pathogenesis of impaired iron release. Br J Haematol 37:7-16, 1997.
66. Hazard JT, Drysdale JW: Ferritinaemia in cancer. Nature 265:755-756, 1977.
67. Tamura T, Goldenberg RL, Johnston KE, et al: Effect of smoking on plasma ferritin concentrations in pregnant women. Clin Chem 41:1190-1191, 1995.
68. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995.
69. Macdougall IC, Tucker B, Thompson J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996.
70. Wingard RL, Parker RA, Ismail N, et al: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995.
71. Kooistra MP, van Es A, Struyvenberg A, et al: Low iron absorption in erythropoietin-treated hemodialysis patients (abstract). J Am Soc Nephrol 6:543, 1995.
72. Eschbach JW, Cook JD, Scribner BH, et al: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977.
73. Taylor JE, Peat N, Porter C, et al: Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996.
74. Sepandj F, Jindal K, West M, et al: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996.
75. Silverberg DS, Blum M, Peer G, et al: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996.
76. Senger JM, Weiss RJ: Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 23:319-323, 1996.
77. Granolleras C, Oulès R, Branger B, et al: Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy, in Bauer C, Koch KM, Scigalla P, et al (eds): Erythropoietin: Molecular Physiology and Clinical Applications, pp 211-218. New York. Marcel Dekker, 1993.
78. Suh H, Wadhwa NK: Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 8:464-466, 1992.
79. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996.
80. Fishbane S, Trenkle J, Maesaka JK: Utilizing continuous quality improvement techniques in dialysis: Application to anemia management. Semin Dial 11:38-44, 1998.
81. Fairbanks VF, Beutler E: Iron deficiency, in Beutler E, Lichtman MA, Coller BS, et al (eds): Williams Hematology, 5th ed, pp 490-510. New York, McGraw-Hill, Inc. 1995.
82. Roe DJ, Harford AM, Zager PG, et al: Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis 28:855-860, 1996.
83. Fishbane S, Ungureanu VD, Maesaka JK, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996.
84. Hamstra RD, Block MH, Schocket AL: Intravenous iron dextran in clinical medicine. JAMA 243:1726-1731, 1980.
85. Schaefer RM, Schaefer L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992.
86. Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57:175-182, 1991.
87. 1 is safe and effective in hemodialysis patients: North American trial (abstract). J Am Soc Nephrol 7:1459, 1996.
88. Amgen, Inc., Thousand Oaks, California: Procrit prescribing information.